Effects of Tildrakizumab on T Cells in Psoriatic Patients, 38 Subjects

A clinical dataset from a study investigating the immunological impact of tildrakizumab treatment on 38 patients with moderate-to-severe psoriasis. The data likely contains longitudinal measurements of circulating T cell subsets, autoantigen reactivity, and clinical scores. It was authored by Paola Facheris and last updated on April 10, 2026.

Use Cases

• Modeling the correlation between Ki67+ T cell frequencies and clinical improvement (PASI) based on the described positive correlation.
• Analyzing longitudinal changes in specific T cell subsets (e.g., Ki67+CD4+, Th17) during treatment based on the flow cytometry results.
• Investigating differences in long-term clinical response between LL37-reactive and non-reactive patient subgroups based on the conclusions.
• Studying the induction of Th17- and Th1-related cytokines by autoantigen stimulation based on the results section.

Strengths

• Includes data from 38 psoriatic patients and 33 healthy donors, providing a control group.
• Contains longitudinal data analyzed using multiparametric flow cytometry, suggesting detailed immunological profiling.
• Released under a permissive CC-BY-4.0 license, allowing for reuse and redistribution.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in scale (1008.1 KB), indicating limited scope.

Provenance

Source

figshare, authored by Paola Facheris.

Collection Method

Data collected from a clinical study where patients were treated with tildrakizumab and analyzed using flow cytometry.

Time Range

The study period is not specified in the provided metadata.

Freshness

Last updated 2026-04-10 05:58:10; freshness should be verified.

Geography

The geographic coverage of the patient cohort is not specified.